Amyris (AMRS) Trading Up -2.2%

Amyris Inc (NASDAQ:AMRS) shares were up 2.2% during trading on Monday . The stock traded as high as $5.51 and last traded at $5.22. Approximately 18,475 shares traded hands during trading, a decline of 97% from the average daily volume of 619,291 shares. The stock had previously closed at $5.34.

A number of research analysts have recently issued reports on AMRS shares. B. Riley started coverage on Amyris in a report on Thursday, January 25th. They issued a “buy” rating and a $8.00 target price on the stock. Zacks Investment Research lowered Amyris from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. ValuEngine raised Amyris from a “strong sell” rating to a “sell” rating in a report on Friday, February 23rd. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Amyris in a report on Monday, April 2nd. Finally, BidaskClub lowered Amyris from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 17th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Amyris currently has an average rating of “Buy” and an average price target of $9.13.

The firm has a market cap of $273.46 million, a PE ratio of -1.74 and a beta of 0.15. The company has a quick ratio of 0.93, a current ratio of 0.67 and a debt-to-equity ratio of -0.35.

Amyris (NASDAQ:AMRS) last released its earnings results on Monday, May 14th. The biotechnology company reported ($1.79) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($1.31). The firm had revenue of $23.00 million during the quarter, compared to analyst estimates of $24.12 million. The company’s revenue for the quarter was up 77.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.13) earnings per share. research analysts anticipate that Amyris Inc will post -1.92 earnings per share for the current fiscal year.

In related news, major shareholder (Mauritius) Pte Ltd Maxwell sold 95,162 shares of the company’s stock in a transaction on Monday, May 7th. The stock was sold at an average price of $6.54, for a total transaction of $622,359.48. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 21.80% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. KBC Group NV grew its holdings in Amyris by 37.4% during the first quarter. KBC Group NV now owns 62,465 shares of the biotechnology company’s stock worth $418,000 after acquiring an additional 16,995 shares during the period. BlackRock Inc. grew its holdings in Amyris by 139.2% during the first quarter. BlackRock Inc. now owns 53,414 shares of the biotechnology company’s stock worth $358,000 after acquiring an additional 31,083 shares during the period. Element Capital Management LLC acquired a new position in Amyris during the first quarter worth $227,000. Compagnie Lombard Odier SCmA grew its holdings in Amyris by 60.0% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock worth $390,000 after acquiring an additional 39,000 shares during the period. Finally, B. Riley Financial Inc. acquired a new position in Amyris during the first quarter worth $294,000. 23.95% of the stock is currently owned by hedge funds and other institutional investors.

Amyris Company Profile

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply